Abstract
Our life is closely linked to microorganisms, either through a parasitic or symbiotic relationship. The microbiome contains more than 1,000 different bacterial species and outnumbers human genes by 150 times. Worryingly, during the last 10 years, it has been observed a relationship between alterations in microbiota and neurodegeneration. Several publications support the hypothesis that amyloid structures formed by microorganisms may trigger host proteins aggregation. In this review, we collect pieces of evidence supporting that the crosstalk between human and microbiota amyloid proteins could be feasible and, probably, a more common event than expected before. The combination of their outnumbers, the long periods of time that stay in our bodies, and the widespread presence of amyloid proteins in the bacteria Domain outline a worrying scenario. However, the identification of the exact microorganisms and the mechanisms through with they can influence human disease also opens the door to developing a new and diverse set of therapeutic strategies.
Introduction
In 2009 the composition of the human microbiome (∼1013 microbial cells) was published (Figure 1). The largest microbial community resides in the gut, where microbial cells outnumber human cells by about 10:1 and their genes by about 100:1(NIH Human Microbiome Project—HMRGD, 2022; Qin et al., 2010). Most of these cells are bacteria, and fungi just represent between 1% and 2% of the biomass (Iliev and Cadwell, 2021). According to these estimations, the microbiota has been designated as the largest “diffuse organ system” in the human body. But more important than its size is its metabolic activity, which is larger than the liver and supports many vital processes (Hill and Lukiw, 2015). Gut microbiota contributes to carbohydrate fermentation and absorption, competes with pathogens, metabolizes and neutralizes dietary carcinogens, and takes part in innate immunity supporting infection and disease resistance (Bhattacharjee and Lukiw, 2013). Thanks to the gut-brain bidirectional communication system, it also influences neuroinflammation, neuromodulation, and neurotransmission (Zhao et al., 2015). In parallel, microorganisms can also colonize our bodies through parasitic and pathogenic mechanisms (Hill et al., 2014).
FIGURE 1
Microbiome impact on amyloidogenesis. The gut microbiome is composed of approximately 1014 bacteria and contains 4.67 bacterial genes. The prion prediction tools have measured approximately 0.3% prions per genome. In the microbiome, this can result in approximately 1.385 genes coding for prion-like domains. The expression of these genes can produce a large number of polypeptide sequences with the potential to form amyloid fibrils. These aggregates may have the ability to interfere with and cross-seed human proteins. The gut and the brain are interconnected by a bidirectional axis. In addition, it has been reported that changes in microbiota composition are related to neurodegenerative diseases. Overall, the administration of probiotics could be a potential therapeutic strategy to treat these disorders.
Microbiota composition can be affected by several factors such as age, gender, environment, diet, or medical treatments (Hill et al., 2014; Miller et al., 2021). These compositional changes can lead to dysbiosis and the consequent disturbance of human health. As follows, microbiota imbalance has been associated with autoimmune and inflammatory disorders (inflammatory bowel disease, asthma, allergies) and with the acceleration of chronic diseases such as cardiovascular disease, obesity, diabetes or cancer (Wilkins et al., 2019; Miller et al., 2021; Liu et al., 2022). Also, several recent studies have identified microbiota dysbiosis in patients affected by different neurodegenerative diseases pointing to a possible connection between the gut microbiota and the origin of neurological disorders (Figure 1) (Rogers et al., 2016; Friedland and Chapman, 2017).
The accumulation of amyloid fibrils in the brain is a common hallmark associated with neurodegenerative diseases, such as Alzheimer’s or Parkinson’s. Despite that in each disorder the aggregates are composed of different proteins, the biophysical properties that define the amyloid structure are the same (Tjernberg et al., 2016; Walker et al., 2016). Interestingly, amyloid fibrils are highly resistant and organized and their conformation can be transmitted, in a prion-like manner, to other proteins even without sequential similarities (Table 1) (Zhou et al., 2012; Kosolapova et al., 2020; Subedi et al., 2022). These special properties have been exploited for different biological functions in all kingdoms of life (Iglesias et al., 2015; Cámara-Almirón et al., 2018). However, the amyloid structure entails an inherent risk that, without control, could lead to a succession of tragic events able to cross the species barrier, such as in the case of the transmissible spongiform encephalopathies (Zhou et al., 2012; Revilla-García et al., 2020; Sampson et al., 2020).
TABLE 1
| Exogenous protein | Organism | Human protein | Interaction effect | References |
|---|---|---|---|---|
| FapC | Pseudomonas | α-synuclein | Accelerates | Christensen et al. (2019) |
| FapC | Pseudomonas | Amyloid-β peptide | Accelerates | Javed et al. (2020) |
| CsgA | Escherichia coli | α-synuclein | Accelerates | Sampson et al. (2020) |
| CsgA, CsgB | Escherichia coli | PAP | Accelerates | Hartman et al. (2013) |
| CsgA, CsgB | Escherichia coli | Amyloid-β peptide | Accelerates | Hartman et al. (2013) |
| CsgA, CsgB | Escherichia coli | IAPP | Accelerates | Hartman et al. (2013) |
| LPS endotoxin | Gram-negative bacteria | α-synuclein | Accelerates and induces distinct strains | Kim et al. (2016) |
| Sup35 | Saccharomyces cerevisiae | Amyloid-β peptide | Accelerates | Koloteva-Levine et al. (2021) |
| β-parvalbumin | Fish | α-synuclein | Inhibits | Werner et al. (2018) |
| β-lactoglobulin | Bovine milk | α-synuclein | Accelerates | Vaneyck et al. (2021) |
| Lysozyme | Chicken egg white | α-synuclein | Accelerates | Vaneyck et al. (2021) |
Examples of interspecies interactions between amyloid proteins. List of exogenous amyloid proteins, that can be in the gut, and that interfere with the aggregation of unrelated human amyloid proteins.
The long periods that the microorganisms stay in the body, due to infection or symbiosis, could facilitate amyloid cross-seeding events between host and microorganism (Otzen and Nielsen, 2008; Iglesias et al., 2015). Moreover, recent studies have demonstrated that bacterial amyloid structures can initiate the formation of amyloid aggregates upon interaction with human proteins (Table 1) (Otzen and Nielsen, 2008; Christensen et al., 2019; Revilla-García et al., 2020; Sampson et al., 2020; Vaneyck et al., 2021). Therefore, it is crucial to identify the microorganisms and precise mechanisms that can influence the aggregation of host proteins. This will help to understand their link with human disease and to design new therapeutic strategies, such as microbiome manipulation with probiotics or antibiotics.
Bacteria Produce Amyloids to Deal With the Surrounding World
To understand how human amyloidogenesis could be affected by coexisting with a huge and diverse community of microorganisms, we first should learn about their potential to produce and manipulate amyloid fibrils. In an early work, Larsen and co-workers performed a systematic screening in several habitats (seawater, sludge, and drinking water) and, in all of them, they detected between 5% and 40% of amyloid-positive bacteria, demonstrating that amyloid-forming proteins are widespread in this Domain (Larsen et al., 2007). Later, sequential and structural analyses provided enough information to generate computational tools capable to screen, in whole proteomes, for amyloid-forming proteins and prion-like domains (PrLDs), with potential to propagate the amyloid conformation (Espinosa Angarica et al., 2014; Lancaster et al., 2014; Iglesias et al., 2015; Iglesias et al., 2021; Yuan and Hochschild, 2017; Harrison, 2019). These data show that prion-like proteins are conserved across multiple phyla (Harrison, 2019) and that at least 0.3% of all known bacteria genes encode for PrLDs. However, for certain species, especially pathogenic bacteria such as Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, or Staphylococcus epidermidis, this percentage could be higher and achieve 18% (Espinosa Angarica et al., 2013; Iglesias et al., 2015; Yuan and Hochschild, 2017).
A more detailed analysis shows that bacteria functional amyloids are mainly extracellular (Blanco et al., 2012). This could reduce the potential intracellular toxicity decreasing the cost associated to control it. But more importantly, at this location amyloid-forming proteins can interact with the sounding environment and develop roles of sensing and adaptation. As a result, bacterial amyloid proteins tend to be associated with adhesion, biofilm formation, and invasion (Elliot et al., 2003; Gebbink et al., 2005; Barnhart and Chapman, 2006). Prokaryotes also use the amyloid conformation to regulate toxins activity by inactivating or storing them. An example of this is Microcin E492 (Mcc), a pore-forming bacteriocin produced by Klebsiella pneumoniae. When exported, the monomers and oligomers create cytotoxic pores that induce the lysis of neighbouring bacteria. On the contrary, the amyloid structures act as inactive reservoirs able to sense environmental changes and to identify the right moment to release the monomers (Shahnawaz and Soto, 2012).
Adhesins acquire macromolecular structures to bind external elements and to build biofilms, three-dimensional matrices involved in host colonization (Barnhart and Chapman, 2006; Larsen et al., 2008; Dueholm et al., 2010). Importantly, biofilm formation enhances bacteria resistance to antibiotics. This is a big problem that increases the risk of mortality and health economic costs (Matilla-Cuenca et al., 2021; Sikora and Zahra, 2021). These infections are mainly caused by opportunistic bacteria such as Enterococcus faecium, Staphylococcus aureus, Klebsiellapneumoniae, Acinetobacter baumannii, or Pseudomonas aeruginosa (Ma et al., 2019; Matilla-Cuenca et al., 2021). Between them, S. aureus is one of the most common causes of hospital-acquired bacteremia (Jensen et al., 1999). Remarkably, this specie is equipped with a diverse set of biofilm-forming proteins able to accomplish multiple functions (Kosolapova et al., 2020; Zaman and Andreasen, 2020; Miller et al., 2021). For example, Bap protein develops a dual role, sensing environmental changes and scaffolding biofilm structures in response (Valle et al., 2020).
The expression of functional amyloid-forming proteins entails risk and bacteria must equip themselves with security mechanisms: chaperones that protect from aggregation, spatial compartmentalization, and temporal control. A clear example of this are the extracellular curli fibers that help in cell-to-cell contacts for community behaviour and host colonization (Gophna et al., 2001). Curli extracellular matrix formation is the result of a coordinated action between several structural and scaffolding components. In E. coli these proteins are encoded by seven different genes (csg) divided in two different operons (csgBAC and csgDEFG) (Bhoite et al., 2019). Curli fibrils production follows a precise and specific process, the type VII secretion system also known as the nucleation-precipitation pathway (Desvaux et al., 2009; Bhoite et al., 2019). Another key element are the chaperones CsgC and CsgE that impede the amyloid assembly until the csg proteins are transported outside (Nenninger et al., 2011; Evans et al., 2015; Otzen and Riek, 2019).
Microbiota and Amyloid Diseases
Amyloid diseases are characterised by the aggregation of proteins into amyloid fibrils and their deposition into plaques and intracellular inclusions (Guerreiro and Hardy, 2014; De Groot and Burgas, 2015; Walker et al., 2016). They are the consequence of genetic and environmental factors, together with aging (Pang et al., 2019). During the last 10 years, several works also pointed out that one of these factors could be an altered microbiota (Chen et al., 2021). In fact, microbiome composition also changes with environmental factors and over time (Finlay et al., 2019; Badal et al., 2020; Bosco and Noti, 2021).
Recently, several publications reported altered gut populations in patients with neurodegenerative diseases (Hill-Burns et al., 2017; Peterson, 2020). The gut and the brain are interconnected by a bidirectional axis. Indeed, the gut contains around 100 million neurons, more than the spinal cord or the peripheral nervous system (Uesaka et al., 2016). It has also been identified as the main entrance of prions into the central nervous system in diseases such as bovine spongiform encephalopathy and kuru (Kujala et al., 2011). And it is also the route that allows microbiota and their products (lipopolysaccharides, amyloids, and other metabolites) to bypass the circulatory system (Braniste et al., 2014; Friedland and Chapman, 2017). This, together with the fact that human amyloid proteins such as amyloid-β-peptide (Aβ) can be found in the peripheral circulation and in the cerebrospinal fluid (Tublin et al., 2019; Wang et al., 2021), can favour interspecies encounters and amyloid protein cross-seeding. It is also important to note that Aβ may be specifically designed to interact with microorganisms, acting as an antimicrobial peptide in host immune response. It can form fibrils that trap pathogens and disrupt their membranes (Kumar et al., 2016; Moir et al., 2018).
Recently, Chen et al. (2016) reported a very original study of how bacterial amyloid aggregates affect rat models of Parkinson’s disease. They studied rats with guts colonised by two E. coli strains just differentiated by encoding for curli proteins with different capacity to form amyloid aggregates. Those bacteria expressing the aggregation-prone variant grew in rats with increased alpha-synuclein accumulation and enhanced cerebral inflammation, thus linking the formation of bacteria amyloid with exacerbated neurodegenerative symptoms. Sampson and colleagues transferred different human microbiotas to mice; and observed greater motor impairment in those animals with intestinal microbes from Parkinson’s patients than in those with microorganisms obtained from healthy persons (Sampson et al., 2016). Instead, Harach and co-workers studied the microbiota of mice models of Alzheimer’s disease (Harach et al., 2017). Their results indicate that the overexpression of Aβ generates a mixture of microbes that when transferred into germ-free mice exacerbates the Alzheimer’s pathology. Overall, there is much evidence that microbiota can influence the development of human disease, but how it happens at the molecular level remains elusive.
How Do Microbiota Produced Amyloids Affect Amyloidogenesis
Amyloid fibrils have the intrinsic potential to self-propagate their β-sheet structure and template it on other soluble molecules (Table 1) (Morales et al., 2010). This seeding has been also detected between bacterial and host amyloid proteins (Friedland, 2015; Chen et al., 2016; Eisenberg and Sawaya, 2017). For example, Pseudomonas FapC protein forms amyloid fibrils for biofilm scaffolding, but in the body, these fibrils can trigger Aβ aggregation and influence the development of neurodegenerative diseases (Javed et al., 2020). In addition, curli fibrils from different bacterial species can seed human proteins aggregation both in vitro and in vivo (Lundmark et al., 2005; Zhou et al., 2012). Intriguingly, seeding reactions with heterologous sequences (also called cross-sending) can lead to alternative amyloid strains, fibrils with different conformational properties, that can cause different clinical severities of the same neurodegenerative disease (Chaudhuri et al., 2019; Javed et al., 2020; Ivanova et al., 2021).
The process of amyloid seeding can be influenced by both structural conformation and sequence. On one hand, the cross-seeding is enhanced when more than 70% of the sequence is shared (Wright et al., 2005). On the other hand, there is an increasing number of examples where fibrils, from unrelated sequences, accelerate the aggregation of a protein target more efficiently than its own fibrils (Wright et al., 2005; Dubey et al., 2014; Koloteva-Levine et al., 2021). The common structure responsible for the conformation propagation is thought to be cross-β-sheet, however, in heterologous seeding, these interactions may vary depending on the proteins involved (Ivanova et al., 2021). Amyloid seeding is achieved when the addition of preformed fibrils, in the aggregation reaction, provides compatible nuclei (or seeds) from which new fibrils can grow exponentially. Without seeds, fibrils growth is delayed until the protein monomers achieve to self-assemble and build de novo nuclei, this is a critical phase that can last from minutes to days (Ivanova et al., 2021).
Despite that there are still many questions to be solved at a molecular level, different mechanisms have been proposed to explain the amyloid seeding between heterologous sequences. Two of the most accepted mechanisms are the template-assisted and the conformational selection and population shift. In both cases, the heterologous amyloid fibrils provide an electrostatic environment and hydrophobic surfaces that favour the nucleation and growth of new aggregates (Ren et al., 2019; Koloteva-Levine et al., 2021; Subedi et al., 2022). At the template-assisted mechanism the protein that grows amyloid fibrils faster, or at least the one with more fibrils, seeds the molecules of the other amyloid protein. And at the conformational selection and population shift mechanism, both proteins have a similar number of seeds, and both types of amyloid fibrils adjust their conformations to bind each other and cross-seed (Ren et al., 2019; Ivanova et al., 2021; Subedi et al., 2022).
Microbiome Manipulation as a Therapeutic Strategy
The link between gut dysbiosis and neurodegenerative diseases is inspiring new therapeutic strategies based on microbiota manipulation (Figure 1) (Peterson et al., 2015; Peterson, 2020). This can be achieved with dietary treatments such as probiotics or faecal transplantation. Probiotics consumption can increase the levels of fatty acids in the brain, supporting brain function, learning, memory, and neurogenesis (Strandwitz, 2018; Peterson, 2020). It also can decrease psychological stress, recover immune response, and improve anxiety in patients with chronic fatigue syndrome (Rao et al., 2009; Messaoudi et al., 2011). However, gut microbiota can also be manipulated with antibiotics. In 2016, Minter et al. (2016) showed that the administration of antibiotics, to mouse models of AD, can reduce gut microbial diversity and decrease amyloidosis and neuroinflammation.
In patients with Alzheimer’s disease, probiotics have anti-oxidant and anti-inflammatory effects that ultimately can cause cognitive recovery (Rao et al., 2009; Messaoudi et al., 2011; Bonfili et al., 2017; Kobayashi et al., 2017; Abraham et al., 2019; Deng et al., 2020). Recently, Govindarajan and co-workers studied for 12 weeks the effect of a probiotic milk containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and Lactobacillus fermentum. In this trial, the AD patients presented several improvements including cognitive performance but without a decrease in inflammation or oxidative stress (Leblhuber et al., 2018). Studies on mice models of AD support that transplantation of faecal microbiota from healthy people to patients can improve the composition of the intestinal microbiota and alleviate the disease symptoms (Rogers et al., 2016). Also in mice models, the administration of certain bacteria strains, such as Lactobacillus plantarum or Bifidobacterium breve A1, decreases Aβ deposition and improves the behavioural deficits (Bonfili et al., 2017; Kobayashi et al., 2017; Lee et al., 2018).
Finally, there are also interesting strategies that focus on interfering with the aggregation-prone protein or even use amyloid peptides as therapeutic agents. Recently, Henning-Knechtel et al. (2020), (Abdelrahman et al., 2020), combined the sequence of different amyloid proteins (Prion Protein, Aβ, and NCAM1 glycoprotein), to design cell-penetrating peptide inhibitors of Aβ fibrillation (Tjernberg et al., 1996; Soto et al., 1998; Lowe et al., 2001; Österlund et al., 2019; Abdelrahman et al., 2020). These peptides also prevent the formation of toxic oligomers and can bind both extra- and intracellular Aβ. Therefore, not just microbiota but also its metabolites (such as their amyloid proteins) can be targeted by therapeutic strategies.
Discussion
With a regular and strong structure, amyloid fibrils are produced to develop functional roles in all kingdoms of life. However, their propagation capacity also entails a risk that without control can have fatal consequences. Relevantly, our bodies contain around 2 Kg of microorganisms (Pagliari et al., 2015) encoding in their genes at least 0.3% of potential prion-like sequences (Iglesias et al., 2015). Moreover, these microbes can reside in our bodies for very long periods. All these facts support that interspecies cross-sending may happen more often than previously expected and could be the origin of several health disturbances (Figure 1).
The study of the microbiome is starting to reveal information about our relationship with microorganisms (NIH Human Microbiome Project—HMRGD). However, there are still lots of unsolved questions about how microbiota and their metabolites influence human health and disease. This is a promising area with a broad range of possible strategies that can be based not only on microbiota manipulation but also on interfering with their metabolites.
Statements
Author contributions
MRFG and NSG conceived the manuscript structure. JSC, ASL, MCS, IT, MRFG, and NSG wrote the main manuscript text. JSC, MRFG, and NSG prepared the figures and revised the manuscript.
Funding
This work was funded by grants RYC2019-026752-I and PID2020-117454RA-I00/AEI/10.13039/501100011033 from Ministerio de Ciencia e Innovación and by L’Oréal-UNESCO For Women in Science Programme.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Abdelrahman S. Alghrably M. Lachowicz J. I. Emwas A.-H. Hauser C. A. E. Jaremko M. (20202020). "What Doesn't Kill You Makes You Stronger": Future Applications of Amyloid Aggregates in Biomedicine. Molecules25, 5245–5325. 10.3390/MOLECULES25225245
2
Abraham D. Feher J. Scuderi G. L. Szabo D. Dobolyi A. Cservenak M. et al (2019). Exercise and Probiotics Attenuate the Development of Alzheimer's Disease in Transgenic Mice: Role of Microbiome. Exp. Gerontol.115, 122–131. 10.1016/J.EXGER.2018.12.005
3
Badal V. D. Vaccariello E. D. Murray E. R. Yu K. E. Knight R. Jeste D. V. et al (2020). The Gut Microbiome, Aging, and Longevity: A Systematic Review. Nutrients12, 3759–3825. 10.3390/NU12123759
4
Barnhart M. M. Chapman M. R. (2006). Curli Biogenesis and Function. Annu. Rev. Microbiol.60, 131–147. 10.1146/ANNUREV.MICRO.60.080805.142106
5
Bhattacharjee S. Lukiw W. J. (2013). Alzheimer's Disease and the Microbiome. Front. Cell. Neurosci.7, 1–4. 10.3389/FNCEL.2013.00153
6
Bhoite S. van Gerven N. Chapman M. R. Remaut H. (2019). Curli Biogenesis: Bacterial Amyloid Assembly by the Type VIII Secretion Pathway. EcoSal Plus8, 101128. 10.1128/ECOSALPLUS.ESP-0037-2018
7
Blanco L. P. Evans M. L. Smith D. R. Badtke M. P. Chapman M. R. (2012). Diversity, Biogenesis and Function of Microbial Amyloids. Trends Microbiol.20, 66–73. 10.1016/j.tim.2011.11.005
8
Bonfili L. Cecarini V. Berardi S. Scarpona S. Suchodolski J. S. Nasuti C. et al (2017). Microbiota Modulation Counteracts Alzheimer's Disease Progression Influencing Neuronal Proteolysis and Gut Hormones Plasma Levels. Sci. Rep.7, 2426. 10.1038/s41598-017-02587-2
9
Bosco N. Noti M. (2021). The Aging Gut Microbiome and its Impact on Host Immunity. Genes Immun.22, 289–303. 10.1038/s41435-021-00126-8
10
Braniste V. Al-Asmakh M. Kowal C. Anuar F. Abbaspour A. Tóth M. et al (2014). The Gut Microbiota Influences Blood-Brain Barrier Permeability in Mice. Sci. Transl. Med.6, 263ra158. 10.1126/SCITRANSLMED.3009759
11
Cámara-Almirón J. Caro-Astorga J. de Vicente A. Romero D. (2018). Beyond the Expected: the Structural and Functional Diversity of Bacterial Amyloids. Crit. Rev. Microbiol.44, 653–666. 10.1080/1040841X.2018.1491527
12
Chaudhuri P. Prajapati K. P. Anand B. G. Dubey K. Kar K. (2019). Amyloid Cross-Seeding Raises New Dimensions to Understanding of Amyloidogenesis Mechanism. Ageing Res. Rev.56, 100937. 10.1016/j.arr.2019.100937
13
Chen S. G. Stribinskis V. Rane M. J. Demuth D. R. Gozal E. Roberts A. M. et al (2016). Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans. Sci. Rep.6, 34477. 10.1038/SREP34477
14
Chen Y. Zhou J. Wang L. (2021). Role and Mechanism of Gut Microbiota in Human Disease. Front. Cell. Infect. Microbiol.11, 625913. 10.3389/fcimb.2021.625913
15
Christensen L. F. B. Jensen K. F. Nielsen J. Vad B. S. Christiansen G. Otzen D. E. (2019). Reducing the Amyloidogenicity of Functional Amyloid Protein FapC Increases Its Ability To Inhibit α-Synuclein Fibrillation. ACS Omega4, 4029–4039. JPEG. 10.1021/ACSOMEGA.8B03590/ASSET/IMAGES/LARGE/AO-2018-03590T_0006
16
De Groot N. S. Burgas M. T. (2015). Is Membrane Homeostasis the Missing Link between Inflammation and Neurodegenerative Diseases?Cell. Mol. Life Sci.72, 4795–4805. 10.1007/S00018-015-2038-4
17
Den H. Dong X. Chen M. Zou Z. (2020). Efficacy of Probiotics on Cognition, and Biomarkers of Inflammation and Oxidative Stress in Adults with Alzheimer's Disease or Mild Cognitive Impairment - a Meta-Analysis of Randomized Controlled Trials. Aging12, 4010–4039. 10.18632/AGING.102810
18
Desvaux M. Hébraud M. Talon R. Henderson I. R. (2009). Secretion and Subcellular Localizations of Bacterial Proteins: a Semantic Awareness Issue. Trends Microbiol.17, 139–145. 10.1016/J.TIM.2009.01.004
19
Dua P Z. Y. Dua P. Lukiw W. (2015). Microbial Sources of Amyloid and Relevance to Amyloidogenesis and AlzheimerÂ's Disease (AD). J. Alzheimers Dis. Park.05, 177. 10.4172/2161-0460.1000177
20
Dubey K. Anand B. G. Temgire M. K. Kar K. (2014). Evidence of Rapid Coaggregation of Globular Proteins during Amyloid Formation. Biochemistry53, 8001–8004. 10.1021/BI501333Q
21
Dueholm M. S. Petersen S. V. Sønderkaer M. Larsen P. Christiansen G. Hein K. L. et al (2010). Functional Amyloid in pseudomonas. Mol. Microbiol.77, 1009–1020. 10.1111/j.1365-2958.2010.07269.x
22
Eisenberg D. S. Sawaya M. R. (2017). Structural Studies of Amyloid Proteins at the Molecular Level. Annu. Rev. Biochem.86, 69–95. 10.1146/annurev-biochem-061516-045104
23
Elliot M. A. Karoonuthaisiri N. Huang J. Bibb M. J. Cohen S. N. Kao C. M. et al (2003). The Chaplins: a Family of Hydrophobic Cell-Surface Proteins Involved in Aerial Mycelium Formation inStreptomyces Coelicolor. Genes Dev.17, 1727–1740. 10.1101/gad.264403
24
Espinosa Angarica V. Angulo A. Giner A. Losilla G. Ventura S. Sancho J. (2014). PrionScan: an Online Database of Predicted Prion Domains in Complete Proteomes. BMC Genomics15, 102. 10.1186/1471-2164-15-102
25
Espinosa Angarica V. Ventura S. Sancho J. (2013). Discovering Putative Prion Sequences in Complete Proteomes Using Probabilistic Representations of Q/N-rich Domains. BMC Genomics14, 316. 10.1186/1471-2164-14-316
26
Evans M. L. Chorell E. Taylor J. D. Åden J. Götheson A. Li F. et al (2015). The Bacterial Curli System Possesses a Potent and Selective Inhibitor of Amyloid Formation. Mol. Cell57, 445–455. 10.1016/J.MOLCEL.2014.12.025
27
Finlay B. B. Pettersson S. Melby M. K. Bosch T. C. G. (2019). The Microbiome Mediates Environmental Effects on Aging. Bioessays41, 1800257. 10.1002/BIES.201800257
28
Friedland R. P. Chapman M. R. (2017). The Role of Microbial Amyloid in Neurodegeneration. PLoS Pathog.13, e1006654. 10.1371/journal.ppat.1006654
29
Friedland R. P. (2015). Mechanisms of Molecular Mimicry Involving the Microbiota in Neurodegeneration. Jad45, 349–362. 10.3233/JAD-142841
30
Gebbink M. F. B. G. Claessen D. Bouma B. Dijkhuizen L. Wösten H. A. B. (2005). Amyloids - a Functional Coat for Microorganisms. Nat. Rev. Microbiol.3, 333–341. 10.1038/NRMICRO1127
31
Gophna U. Barlev M. Seijffers R. Oelschlager T. A. Hacker J. Ron E. Z. (2001). Curli Fibers Mediate Internalization of Escherichia coli by Eukaryotic Cells. Infect. Immun.69, 2659–2665. 10.1128/IAI.69.4.2659-2665.2001
32
Guerreiro R. Hardy J. (2014). Genetics of Alzheimer's Disease. Neurotherapeutics11, 732–737. 10.1007/S13311-014-0295-9
33
Harach T. Marungruang N. Duthilleul N. Cheatham V. Mc Coy K. D. Frisoni G. et al (2017). Reduction of Abeta Amyloid Pathology in APPPS1 Transgenic Mice in the Absence of Gut Microbiota. Sci. Rep.7, 41802. 10.1038/SREP41802
34
Harrison P. M. (2019). Evolutionary Behaviour of Bacterial Prion-like Proteins. PLoS One14, e0213030. 10.1371/JOURNAL.PONE.0213030
35
Hartman K. Brender J. R. Monde K. Ono A. Evans M. L. Popovych N. et al (2013). Bacterial Curli Protein Promotes the Conversion of PAP248-286into the Amyloid SEVI: Cross-Seeding of Dissimilar Amyloid Sequences. PeerJ1, e5. 10.7717/PEERJ.5
36
Henning-Knechtel A. Kumar S. Wallin C. Król S. Wärmländer S. K. T. S. Jarvet J. et al (2020). Designed Cell-Penetrating Peptide Inhibitors of Amyloid-Beta Aggregation and Cytotoxicity. Cell Rep. Phys. Sci.1, 100014. 10.1016/J.XCRP.2020.100014
37
Hill J. M. Clement C. Pogue A. I. Bhattacharjee S. Zhao Y. Lukiw W. J. (2014). Pathogenic Microbes, the Microbiome, and Alzheimer's Disease (AD). Front. Aging Neurosci.6, 127. 10.3389/FNAGI.2014.00127/BIBTEX
38
Hill J. M. Lukiw W. J. (2015). Microbial-generated Amyloids and Alzheimer's Disease (AD). Front. Aging Neurosci.7, 9. 10.3389/FNAGI.2015.00009/BIBTEX
39
Hill-Burns E. M. Debelius J. W. Morton J. T. Wissemann W. T. Lewis M. R. Wallen Z. D. et al (2017). Parkinson's Disease and Parkinson's Disease Medications Have Distinct Signatures of the Gut Microbiome. Mov. Disord.32, 739–749. 10.1002/MDS.26942
40
HMRGD (2022). NIH Human Microbiome ProjectAvailable at: https://www.hmpdacc.org/HMRGD/ [Accessed April 15, 2022].
41
Iglesias V. de Groot N. S. Ventura S. (2015). Computational Analysis of Candidate Prion-like Proteins in Bacteria and Their Role. Front. Microbiol.6, 1123. 10.3389/FMICB.2015.01123/BIBTEX
42
Iglesias V. Santos J. Santos-Suárez J. Pintado-Grima C. Ventura S. (2021). SGnn: A Web Server for the Prediction of Prion-Like Domains Recruitment to Stress Granules Upon Heat Stress. Front. Mol. Biosci.8, 718301. 10.3389/FMOLB.2021.718301/BIBTEX
43
Iliev I. D. Cadwell K. (2021). Effects of Intestinal Fungi and Viruses on Immune Responses and Inflammatory Bowel Diseases. Gastroenterology160, 1050–1066. 10.1053/J.GASTRO.2020.06.100
44
Ivanova M. I. Lin Y. Lee Y.-H. Zheng J. Ramamoorthy A. (2021). Biophysical Processes Underlying Cross-Seeding in Amyloid Aggregation and Implications in Amyloid Pathology. Biophys. Chem.269, 106507. 10.1016/j.bpc.2020.106507
45
Javed I. Zhang Z. Adamcik J. Andrikopoulos N. Li Y. Otzen D. E. et al (2020). Accelerated Amyloid Beta Pathogenesis by Bacterial Amyloid FapC. Adv. Sci.7, 2001299. 10.1002/ADVS.202001299
46
Jensen A. G. Wachmann C. H. Poulsen K. B. Espersen F. Scheibel J. Skinhøj P. et al (1999). Risk Factors for Hospital-Acquired Staphylococcus aureus Bacteremia. Arch. Intern. Med.159, 1437–1444. 10.1001/ARCHINTE.159.13.1437
47
Kim C. Lv G. Lee J. S. Jung B. C. Masuda-Suzukake M. Hong C.-S. et al (2016). Exposure to Bacterial Endotoxin Generates a Distinct Strain of α-synuclein Fibril. Sci. Rep.6, 30891. 10.1038/SREP30891
48
Kobayashi Y. Sugahara H. Shimada K. Mitsuyama E. Kuhara T. Yasuoka A. et al (2017). Therapeutic Potential of Bifidobacterium Breve Strain A1 for Preventing Cognitive Impairment in Alzheimer's Disease. Sci. Rep.7, 1–10. 10.1038/s41598-017-13368-2
49
Koloteva-Levine N. Aubrey L. D. Marchante R. Purton T. J. Hiscock J. R. Tuite M. F. et al (2021). Amyloid Particles Facilitate Surface-Catalyzed Cross-Seeding by Acting as Promiscuous Nanoparticles. Proc. Natl. Acad. Sci. U. S. A.118, e2104148118. 10.1073/PNAS.2104148118/-/DCSUPPLEMENTAL
50
Kosolapova A. O. Antonets K. S. Belousov M. V. Nizhnikov A. A. (2020). Biological Functions of Prokaryotic Amyloids in Interspecies Interactions: Facts and Assumptions. Ijms.21, 7240. 10.3390/IJMS21197240
51
Kujala P. Raymond C. R. Romeijn M. Godsave S. F. van Kasteren S. I. Wille H. et al (2011). Prion Uptake in the Gut: Identification of the First Uptake and Replication Sites. PLOS Pathog.7, e1002449. 10.1371/JOURNAL.PPAT.1002449
52
Kumar D. K. V. Choi S. H. Washicosky K. J. Eimer W. A. Tucker S. Ghofrani J. et al (2016). Amyloid-β Peptide Protects against Microbial Infection in Mouse and Worm Models of Alzheimer's Disease. Sci. Transl. Med.8, 340ra72. 10.1126/SCITRANSLMED.AAF1059
53
Lancaster A. K. Nutter-Upham A. Lindquist S. King O. D. (2014). PLAAC: a Web and Command-Line Application to Identify Proteins with Prion-like Amino Acid Composition. Bioinformatics30, 2501–2502. 10.1093/BIOINFORMATICS/BTU310
54
Larsen P. Nielsen J. L. Dueholm M. S. Wetzel R. Otzen D. Nielsen P. H. (2007). Amyloid Adhesins Are Abundant in Natural Biofilms. Environ. Microbiol.9, 3077–3090. 10.1111/j.1462-2920.2007.01418.x
55
Larsen P. Nielsen J. L. Otzen D. Nielsen P. H. (2008). Amyloid-like Adhesins Produced by Floc-Forming and Filamentous Bacteria in Activated Sludge. Appl. Environ. Microbiol.74, 1517–1526. 10.1128/AEM.02274-07
56
Leblhuber F. Egger M. Schuetz B. Fuchs D. (2018). Commentary: Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer's Disease: A Randomized, Double-Blind and Controlled Trial. Front. Aging Neurosci.10, 54. 10.3389/FNAGI.2018.00054
57
Lee H.-J. Hwang Y.-H. Kim D.-H. (2018). Lactobacillus Plantarum C29-Fermented Soybean (DW2009) Alleviates Memory Impairment in 5XFAD Transgenic Mice by Regulating Microglia Activation and Gut Microbiota Composition. Mol. Nutr. Food Res.62, 1800359. 10.1002/MNFR.201800359
58
Liu H. Liu H. Liu C. Shang M. Wei T. Yin P. (2022). Gut Microbiome and the Role of Metabolites in the Study of Graves’ Disease. Front. Mol. Biosci.9, 150. 10.3389/FMOLB.2022.841223/BIBTEX
59
Lowe T. L. Strzelec A. Kiessling L. L. Murphy R. M. (2001). Structure−Function Relationships for Inhibitors of β-Amyloid Toxicity Containing the Recognition Sequence KLVFF. Biochemistry40, 7882–7889. 10.1021/BI002734U
60
Lundmark K. Westermark G. T. Olsén A. Westermark P. (2005). Protein Fibrils in Nature Can Enhance Amyloid Protein A Amyloidosis in Mice: Cross-Seeding as a Disease Mechanism. Proc. Natl. Acad. Sci. U.S.A.102, 6098–6102. 10.1073/PNAS.0501814102
61
Ma Y. X. Wang C. Y. Li Y. Y. Li J. Wan Q. Q. Chen J. H. et al (2019). Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections. Adv. Sci.7, 1901872. 10.1002/ADVS.201901872
62
Matilla-Cuenca L. Toledo-Arana A. Valle J. (2021). Anti-Biofilm Molecules Targeting Functional Amyloids. Antibiotics.10, 795. 10.3390/ANTIBIOTICS10070795
63
Messaoudi M. Lalonde R. Violle N. Javelot H. Desor D. Nejdi A. et al (2011). Assessment of Psychotropic-like Properties of a Probiotic Formulation (Lactobacillus helveticusR0052 andBifidobacterium longumR0175) in Rats and Human Subjects. Br. J. Nutr.105, 755–764. 10.1017/S0007114510004319
64
Miller A. L. Bessho S. Grando K. Tükel Ç. (2021). Microbiome or Infections: Amyloid-Containing Biofilms as a Trigger for Complex Human Diseases. Front. Immunol.12, 638867. 10.3389/fimmu.2021.638867
65
Minter M. R. Zhang C. Leone V. Ringus D. L. Zhang X. Oyler-Castrillo P. et al (2016). Antibiotic-induced Perturbations in Gut Microbial Diversity Influences Neuro-Inflammation and Amyloidosis in a Murine Model of Alzheimer's Disease. Sci. Rep.6, 30028. 10.1038/SREP30028
66
Moir R. D. Lathe R. Tanzi R. E. (2018). The Antimicrobial Protection Hypothesis of Alzheimer's Disease. Alzheimer's & Dement.14, 1602–1614. 10.1016/J.JALZ.2018.06.3040
67
Morales R. Estrada L. D. Diaz-Espinoza R. Morales-Scheihing D. Jara M. C. Castilla J. et al (2010). Molecular Cross Talk between Misfolded Proteins in Animal Models of Alzheimer's and Prion Diseases. J. Neurosci.30, 4528–4535. 10.1523/JNEUROSCI.5924-09.2010
68
Nenninger A. A. Robinson L. S. Hammer N. D. Epstein E. A. Badtke M. P. Hultgren S. J. et al (2011). CsgE Is a Curli Secretion Specificity Factor that Prevents Amyloid Fibre Aggregation. Mol. Microbiol.81, 486–499. 10.1111/J.1365-2958.2011.07706.X
69
Österlund N. Luo J. Wärmländer S. K. T. S. Gräslund A. (2019). Membrane-mimetic Systems for Biophysical Studies of the Amyloid-β Peptide. Biochimica Biophysica Acta (BBA) - Proteins Proteomics1867, 492–501. 10.1016/J.BBAPAP.2018.11.005
70
Otzen D. Nielsen P. H. (2008). We Find Them Here, We Find Them There: Functional Bacterial Amyloid. Cell. Mol. Life Sci.65, 910–927. 10.1007/S00018-007-7404-4
71
Otzen D. Riek R. (2019). Functional Amyloids. Cold Spring Harb. Perspect. Biol.11, a033860. 10.1101/CSHPERSPECT.A033860
72
Pagliari D. Piccirillo C. A. Larbi A. Cianci R. (2015). The Interactions between Innate Immunity and Microbiota in Gastrointestinal Diseases. J. Immunol. Res.2015, 1–3. 10.1155/2015/898297
73
Pang S. Y.-Y. Ho P. W.-L. Liu H.-F. Leung C.-T. Li L. Chang E. E. S. et al (2019). The Interplay of Aging, Genetics and Environmental Factors in the Pathogenesis of Parkinson's Disease. Transl. Neurodegener.8, 23. 10.1186/S40035-019-0165-9
74
Peterson C. T. (2020). Dysfunction of the Microbiota-Gut-Brain Axis in Neurodegenerative Disease: The Promise of Therapeutic Modulation With Prebiotics, Medicinal Herbs, Probiotics, and Synbiotics. J. Evid. Based Complement. Altern. Med.25, 2515690X2095722. 10.1177/2515690X20957225
75
Peterson C. T. Sharma V. Elmén L. Peterson S. N. (2015). Immune Homeostasis, Dysbiosis and Therapeutic Modulation of the Gut Microbiota. Clin. Exp. Immunol.179, 363–377. 10.1111/CEI.12474
76
Qin J. Li R. Li R. Raes J. Arumugam M. Burgdorf K. S. et al (2010). A Human Gut Microbial Gene Catalogue Established by Metagenomic Sequencing. Nature464, 59–65. 10.1038/nature08821
77
Rao A. V. Bested A. C. Beaulne T. M. Katzman M. A. Iorio C. Berardi J. M. et al (2009). A Randomized, Double-Blind, Placebo-Controlled Pilot Study of a Probiotic in Emotional Symptoms of Chronic Fatigue Syndrome. Gut Pathog.1, 6. 10.1186/1757-4749-1-6
78
Ren B. Zhang Y. Zhang M. Liu Y. Zhang D. Gong X. et al (2019). Fundamentals of Cross-Seeding of Amyloid Proteins: an Introduction. J. Mat. Chem. B7, 7267–7282. 10.1039/C9TB01871A
79
Revilla-García A. Fernández C. Moreno-del Álamo M. de los Ríos V. Vorberg I. M. Giraldo R. (2020). Intercellular Transmission of a Synthetic Bacterial Cytotoxic Prion-like Protein in Mammalian Cells. MBio11, e02937–19. 10.1128/mBio.02937-19
80
Rogers G. B. Keating D. J. Young R. L. Wong M.-L. Licinio J. Wesselingh S. (2016). From Gut Dysbiosis to Altered Brain Function and Mental Illness: Mechanisms and Pathways. Mol. Psychiatry21, 738–748. 10.1038/mp.2016.50
81
Sampson T. R. Challis C. Jain N. Moiseyenko A. Ladinsky M. S. Shastri G. G. et al (2020). A Gut Bacterial Amyloid Promotes α-synuclein Aggregation and Motor Impairment in Mice. Elife9, e53111. 10.7554/eLife.53111
82
Sampson T. R. Debelius J. W. Thron T. Janssen S. Shastri G. G. Ilhan Z. E. et al (2016). Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. Cell167, 1469–1480. e12. 10.1016/J.CELL.2016.11.018
83
Shahnawaz M. Soto C. (2012). Microcin Amyloid Fibrils A Are Reservoir of Toxic Oligomeric Species. J. Biol. Chem.287, 11665–11676. 10.1074/jbc.M111.282533
84
Sikora A. Zahra F. (2021). “Nosocomial Infections,” in StatPearls (Treasure Island (FL): StatPearls Publishing).
85
Soto C. Sigurdsson E. M. Morelli L. Asok Kumar R. Castaño E. M. Frangione B. (1998). β-Sheet Breaker Peptides Inhibit Fibrillogenesis in a Rat Brain Model of Amyloidosis: Implications for Alzheimer's Therapy. Nat. Med.4, 822–826. 10.1038/NM0798-822
86
Strandwitz P. (2018). Neurotransmitter Modulation by the Gut Microbiota. Brain Res.1693, 128–133. 10.1016/J.BRAINRES.2018.03.015
87
Subedi S. Sasidharan S. Nag N. Saudagar P. Tripathi T. (2022). Amyloid Cross-Seeding: Mechanism, Implication, and Inhibition. Molecules27, 1776. 10.3390/MOLECULES27061776
88
Tjernberg L. O. Näslund J. Lindqvist F. Johansson J. Karlström A. R. Thyberg J. et al (1996). Arrest of -Amyloid Fibril Formation by a Pentapeptide Ligand. J. Biol. Chem.271, 8545–8548. 10.1074/JBC.271.15.8545
89
Tjernberg L. O. Rising A. Johansson J. Jaudzems K. Westermark P. (2016). Transmissible Amyloid. J. Intern. Med.280, 153–163. 10.1111/JOIM.12499
90
Tublin J. M. Adelstein J. M. Del Monte F. Combs C. K. Wold L. E. (2019). Getting to the Heart of Alzheimer Disease. Circ. Res.124, 142–149. 10.1161/CIRCRESAHA.118.313563
91
Uesaka T. Young H. M. Pachnis V. Enomoto H. (2016). Development of the Intrinsic and Extrinsic Innervation of the Gut. Dev. Biol.417, 158–167. 10.1016/J.YDBIO.2016.04.016
92
Valle J. Fang X. Lasa I. (2020). Revisiting Bap Multidomain Protein: More Than Sticking Bacteria Together. Front. Microbiol.11, 3345. 10.3389/FMICB.2020.613581/BIBTEX
93
Vaneyck J. Segers-Nolten I. Broersen K. Claessens M. M. A. E. (2021). Cross-seeding of Alpha-Synuclein Aggregation by Amyloid Fibrils of Food Proteins. J. Biol. Chem.296, 100358. 10.1016/J.JBC.2021.100358
94
Walker L. C. Schelle J. Jucker M. (2016). The Prion-Like Properties of Amyloid-β Assemblies: Implications for Alzheimer's Disease. Cold Spring Harb. Perspect. Med.6, a024398. 10.1101/CSHPERSPECT.A024398
95
Wang D. Chen F. Han Z. Yin Z. Ge X. Lei P. (2021). Relationship Between Amyloid-β Deposition and Blood-Brain Barrier Dysfunction in Alzheimer's Disease. Front. Cell. Neurosci.15, 695479. 10.3389/FNCEL.2021.695479
96
Werner T. Kumar R. Horvath I. Scheers N. Wittung-Stafshede P. (2018). Abundant Fish Protein Inhibits α-synuclein Amyloid Formation. Sci. Rep.8, 5465. 10.1038/S41598-018-23850-0
97
Wilkins L. J. Monga M. Miller A. W. (20192019). Defining Dysbiosis for a Cluster of Chronic Diseases. Sci. Rep.9, 1–10. 10.1038/s41598-019-49452-y
98
Wright C. F. Teichmann S. A. Clarke J. Dobson C. M. (2005). The Importance of Sequence Diversity in the Aggregation and Evolution of Proteins. Nature438, 878–881. 10.1038/nature04195
99
Yuan A. H. Hochschild A. (2017). A Bacterial Global Regulator Forms a Prion. Science.355, 198–201. SM.PDF. 10.1126/SCIENCE.AAI7776/SUPPL_FILE/YUAN
100
Zaman M. Andreasen M. (2020). Cross-talk between Individual Phenol-Soluble Modulins in Staphylococcus aureus Biofilm Enables Rapid and Efficient Amyloid Formation. Elife9, e59776. 10.7554/ELIFE.59776
101
Zhou Y. Smith D. Leong B. J. Brännström K. Almqvist F. Chapman M. R. (2012). Promiscuous Cross-Seeding between Bacterial Amyloids Promotes Interspecies Biofilms. J. Biol. Chem.287, 35092–35103. 10.1074/jbc.M112.383737
Summary
Keywords
microbiome, amyloid, prion, bacteria, probiotic, neurodegenerative disease, gut
Citation
Seira Curto J, Surroca Lopez A, Casals Sanchez M, Tic I, Fernandez Gallegos MR and Sanchez de Groot N (2022) Microbiome Impact on Amyloidogenesis. Front. Mol. Biosci. 9:926702. doi: 10.3389/fmolb.2022.926702
Received
23 April 2022
Accepted
27 May 2022
Published
16 June 2022
Volume
9 - 2022
Edited by
Verena Kohler, Stockholm University, Sweden
Reviewed by
Sangyong Jung, Institute of Molecular and Cell Biology (A∗STAR), Singapore
Updates
Copyright
© 2022 Seira Curto, Surroca Lopez, Casals Sanchez, Tic, Fernandez Gallegos and Sanchez de Groot.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maria Rosario Fernandez Gallegos, rosario.fernandez@uab.cat; Natalia Sanchez de Groot, natalia.sanchez@uab.cat
This article was submitted to Protein Biochemistry for Basic and Applied Sciences, a section of the journal Frontiers in Molecular Biosciences
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.